Treatment(s) already received-Hormonal therapy - Page 2 of 8 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Hormonal therapy Posts on Medivizor

The use of curcumin in prostate cancer

Posted by on Feb 5, 2019 in Prostate cancer | 0 comments

In a nutshell This study looked at the effect of curcumin on prostate cancer. It concluded that curcumin taken for 6 months was safe but did not reduce the need for hormone suppression therapy.  Some background Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate cancer can be treated by medication,...

Read More

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...

Read More

Guidelines for the use of hormone therapy in hormone receptor-positive patients with metastatic breast cancer.

Posted by on Aug 1, 2017 in Breast cancer | 0 comments

In a nutshell This report aimed to develop recommendations for endocrine therapy in women with hormone receptor-positive metastatic breast cancer. Some background Endocrine therapy, also known as hormone therapy (HT) is used to treat hormone receptor (HR) positive metastatic breast cancer (MBC). HR positive MBC depends on the hormones estrogen or...

Read More

Is abemaciclib combined with fulvestrant effective in women with HR positive advanced breast cancer?

Posted by on Jul 15, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the effectiveness of the combination of fulvestrant (Faslodex) and abemaciclib to fulvestrant alone in patients with advanced breast cancer. This study concluded that the combination of fulvestrant and abemaciclib had improved outcomes for patients when compared to fulvestrant alone.  Some background...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Can the neutrophil to lymphocyte ratio predict outcome in enzalutamide-treated prostate cancer patients?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide.  Some background Treatment for metastatic...

Read More